-
公开(公告)号:US12257318B2
公开(公告)日:2025-03-25
申请号:US18431504
申请日:2024-02-02
Applicant: ReCode Therapeutics, Inc.
Inventor: Mirko Hennig , Daniella Ishimaru , David J. Lockhart , Michael Torres , Jackson Eby , Dmitri Boudko , Brandon A. Wustman
Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.
-
公开(公告)号:US20240309376A1
公开(公告)日:2024-09-19
申请号:US18532995
申请日:2023-12-07
Applicant: ReCode Therapeutics, Inc.
Inventor: Michael Torres , Dmitri Boudko , Ella Meleshkevitch , Melissa Coquelin
IPC: C12N15/113 , A61K9/00 , A61K9/51 , A61P11/00
CPC classification number: C12N15/113 , A61K9/0078 , A61K9/5123 , A61P11/00 , C12N2310/11 , C12N2310/531
Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may be or encode a synthetic transfer ribonucleic acid (tRNA). The polynucleotide may be assembled with a lipid composition for delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of cystic fibrosis transmembrane conductance regulator (CFTR) protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.
-
公开(公告)号:US20250019409A1
公开(公告)日:2025-01-16
申请号:US18283523
申请日:2022-03-23
Applicant: ReCode Therapeutics, Inc.
Inventor: Mirko Hennig , Daniella Ishimaru , David J. Lockhart , Michael Torres , Jackson Eby , Dmitri Boudko , Brandon A. Wustman
Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.
-
公开(公告)号:US20240269325A1
公开(公告)日:2024-08-15
申请号:US18431504
申请日:2024-02-02
Applicant: ReCode Therapeutics, Inc.
Inventor: Mirko Hennig , Daniella Ishimaru , David J. Lockhart , Michael Torres , Jackson Eby , Dmitri Boudko , Brandon Wustman
CPC classification number: A61K48/005 , A61K9/0078 , A61K9/12 , A61K9/1271 , A61K9/5123 , A61K38/1709 , A61K48/0075
Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.
-
-
-